My Health

My Health is a Belgian clinical-stage biotech company specializing in innovative microbiome solutions, particularly spore-forming probiotics known as sporebiotics. Founded in 2017 by Raf Dybajlo, the company focuses on addressing chronic functional diseases such as functional dyspepsia and recurrent vulvovaginal candidiasis through its proprietary strains, MY01 and MY02. My Health achieved a major scientific milestone by publishing a successful clinical study in The Lancet Gastroenterology & Hepatology, demonstrating the efficacy of its strains in treating unexplained stomach complaints. In early 2024, the company entered a strategic partnership with the Biocodex Group, which included a licensing agreement and a 20% minority investment to accelerate international commercialization. The company's product portfolio, marketed under the MY®HEALTH brand, includes scientifically validated supplements for digestive, immune, and women's health. My Health collaborates extensively with academic research labs in Belgium to develop new solutions for unmet medical needs.